SCHEMBL3771986

SCHEMBL3771986

COc1ccc(-c2ccc(-c3ccc(N4CCN(CC(=O)N5CCN(C6CCC6)CC5)CC4)nn3)cc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.49
HRH3 Q9Y5N1 4/20 0.48
ALDH1A1 P00352 4/20 0.48
KMT2A Q03164 2/20 0.48
TSHR P16473 1/20 0.48
MAPT P10636 3/20 0.47
MAPK1 P28482 1/20 0.47
RAB9A P51151 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
KDM4E B2RXH2 2/20 0.44
HPGD P15428 1/20 0.44
HSD17B10 Q99714 1/20 0.44
KDM2B Q8NHM5 2/20 0.43
TP53 P04637 1/20 0.42
LMNA P02545 2/20 0.42
GAA P10253 1/20 0.42
TLR9 Q9NR96 1/20 0.41
TLR7 Q9NYK1 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
ORAI1 Q96D31 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3770163 0.99 HRH3 (0.49) ACHEHRH3ALDH1A1KMT2ATSHR
SCHEMBL3767881 0.91 HRH3 (0.47) ACHEHRH3ALDH1A1KMT2ATSHR
SCHEMBL3763141 0.90 ALDH1A1 (0.48) ACHEHRH3ALDH1A1KMT2AMAPT
SCHEMBL3767453 0.89 HRH3 (0.45) HRH3ALDH1A1KMT2ATSHRMAPT
SCHEMBL3767549 0.89 MAPK1 (0.50) HRH3ALDH1A1TSHRMAPTMAPK1
SCHEMBL3769187 0.89 ALDH1A1 (0.45) ACHEHRH3ALDH1A1KMT2AMAPT
SCHEMBL13006478 0.88 HRH3 (0.46) ACHEHRH3ALDH1A1TSHRMAPT
SCHEMBL3780455 0.88 PANK3 (0.50) HRH3ALDH1A1KMT2ATSHRMAPT
SCHEMBL3767484 0.88 MAPK1 (0.49) HRH3ALDH1A1KMT2ATSHRMAPT
SCHEMBL3763002 0.87 HRH3 (0.46) HRH3ALDH1A1KMT2AMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 ACHE 2020/4885HRH3 2/4885ALDH1A1 1210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.